Testing a new medication for advanced prostate cancer

Plain-English translation of NCT07570979 on ClinicalTrials.gov ↗ · Source last updated September 2026 · Translation generated July 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

This is one of the first times this treatment has been tested in people.

What is this trial?

This is a first-in-human trial testing a new medication called for men with metastatic castration-resistant prostate cancer—a type of advanced prostate cancer that has stopped responding to standard hormone therapies. You would receive the medication either by itself or combined with one of two existing prostate cancer drugs. The study aims to find the right dose and understand how safe and effective this treatment is.

Current treatments for advanced castration-resistant prostate cancer eventually stop working for many patients, leaving them with limited options. This medication targets a different pathway in cancer cells, and researchers hope it could help patients whose cancer has progressed despite other treatments.

Do you qualify?

You likely qualify if…

you have been diagnosed with metastatic castration-resistant prostate cancer that has progressed despite standard treatments (or you are not a candidate for standard treatments)
you have confirmation of prostate adenocarcinoma through a biopsy or tissue sample
you have at least one area of cancer spread visible on recent imaging scans (within the past 28 days)
your testosterone levels are at castrate levels (very low), either naturally or through ongoing hormone therapy
you are in generally good health with an Eastern Cooperative Oncology Group performance status of 2 or better (able to carry out most daily activities)

You likely don't qualify if…

you are under 18 years old
you have previously been treated with a cereblon-based degrader drug
you are living with HIV or have a compromised immune system
you are currently taking medications known to prolong the QT interval of your heart and cannot stop taking them
you have only a rising prostate-specific antigen (PSA) level without visible spread of cancer on imaging scans

What participation looks like

You would take the oral medication daily (by mouth) either alone or combined with an existing prostate cancer drug, depending on which treatment arm you are assigned to. The study involves multiple visits to the clinic for blood tests, imaging scans, and check-ins to monitor how your body tolerates the medication and how your cancer responds. The study starts with a dose-escalation phase where researchers carefully increase doses to find the safest level, followed by an expansion phase with more patients at that dose to gather additional safety and effectiveness information.

AI-generated summary from trial data · Jul 17, 2026 · Not medical advice

Trial locations(5 sites)

United States

Mary Crowley Cancer Research, Dallas, Texas

Australia

Novartis Investigative Site, Melbourne, Victoria

Canada

Novartis Investigative Site, Montreal, Quebec

Japan

Novartis Investigative Site, Hirakata, Osaka

South Korea

Novartis Investigative Site, Seoul